## Preoperative Embolization in Nasopharyngeal Angiofibroma ### Role of Embolization **Key Point:** Preoperative endovascular embolization is the standard of care to reduce tumor vascularity and intraoperative blood loss in nasopharyngeal angiofibroma (NAF). **High-Yield:** Embolization is performed 24–48 hours before surgical excision to allow collateral circulation to develop while maintaining tumor ischemia. ### Embolic Agents in NAF | Agent | Type | Use in NAF | Mechanism | |-------|------|-----------|----------| | **Polyvinyl alcohol (PVA)** | Particulate | **Gold standard** | Mechanical occlusion of feeding vessels; permanent; particle size 150–500 μm | | Sodium tetradecyl sulfate | Sclerosant | Rarely used | Chemical sclerosis; risk of vessel perforation | | Bleomycin | Chemotherapeutic | Not for embolization | Used in intralesional injection for recurrent/unresectable NAF | | Doxycycline | Antibiotic | Not for embolization | Sclerosant in pleurodesis; not used in NAF | ### Why PVA Is Preferred 1. **Particle size control** — 150–500 μm particles lodge in feeding arteries without proximal occlusion, allowing selective embolization. 2. **Permanent effect** — Does not recanalize; maintains ischemia until surgery. 3. **Safety profile** — Lower risk of vessel rupture or distal embolization compared to liquid agents. 4. **Reduced blood loss** — Decreases operative blood loss from 800–2000 mL to <500 mL. **Clinical Pearl:** Coil embolization is reserved for proximal vessel occlusion when PVA fails or for high-flow feeders; it is not first-line. **Tip:** Remember NAF is a **benign but locally aggressive tumor** — the goal is surgical cure with minimal morbidity. Embolization is an adjunct to surgery, not a standalone treatment. [cite:Scott-Brown's Otorhinolaryngology Ch 46]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.